de Waal L, Lewis TA, Rees MG et al. Identification of cancer cytotoxic modulators of PDE3A by predictive chemogenomics. Nat Chem Biol. 2016;12:102–108.
Imielinski M, Greulich H, Kaplan B et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J. Clin. Invest. 2014; 124, 1582-1586.
Greulich H, Kaplan B, Mertins P et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. PNAS. 2012; 109, 14476-14481.
Heidi Greulich, Ph.D.
Heidi Greulich is a senior group leader in the Cancer Program at the Broad Institute of MIT and Harvard. She leads a group that studies mutations in genes that lead to cancer, with the goal of developing new cancer therapies. Her current research focus is studying the mechanism of action of DNMDP, a small molecule that kills cancer cells expressing elevated levels of two genes, PDE3A and SLFN12. Previous research includes characterization of oncogenic mutations in the extracellular domain of the receptor tyrosine kinase, ERBB2, and novel oncogenic mutations in ARAF associated with a lung cancer patient response to sorafenib. Her main area of expertise is cancer biology with secondary expertise in cancer genomics.
Greulich joined the Broad Institute in 2004 with a joint affiliation with the Dana-Farber Cancer Institute, where she was a researcher and instructor for 12 years before becoming exclusively affiliated with the Broad Institute in 2016. She is the recipient of grants from Uniting Against Lung Cancer, Doctors Cancer Foundation, Lung Cancer Research Foundation, and the NIH Molecular Libraries Probe Production Centers Network.
Greulich holds a Ph.D. in molecular oncology from The Rockefeller University and a bachelor’s degree in molecular biology from Princeton University. Her postdoctoral fellowship was undertaken at Harvard University.
Contact Heidi Greulich via email at firstname.lastname@example.org.